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Altered Glucocorticoid Binding and Action in Response to Epidermal Growth
Factor in HBL100 Cells1
Kanury V. S. Rao, Robert E. Williams, and C. Fred Fox2
Department of Microbiology and Molecular Biology Institute, University of California at Los Angeles, Los Angeles, California 90024-1489
ABSTRACT
Incubation of adherent human breast epithelial HBL100 cells with
epidermal growth factor (EGF) decreased [3H]dexamethasone binding by
35% with no effect on affinity. Maximal inhibition was obtained at 3 n\i
EGF and the 50% effective dose was 0.2 mi EGF. Decreased dexameth-
asone binding induced by 3 n\i EGF was maximal by 5 min of treatment
and, in the continuous presence of EGF, persisted at a constant level over
4 days. The action of EGF was antagonized by 12-O-tetradecanoylphor-
bol-13-acetate, which did not inhibit dexamethasone binding significantly,
and by concanavalin A. In homogenates of EGF-treated cells, decreased
dexamethasone binding was observed only in the cytosolic fraction.
Saturation dexamethasone binding inhibited the growth rate of 11HI 100
cells by approximately 50%, but concurrent treatment with EGF over
came this inhibition. The effect of EGF on dexamethasone-inhibited cell
growth also was antagonized by 12-O-tetradecanoylphorbol-13-acetate.
INTRODUCTION
Glucocorticoids elicit an array of physiological responses in
target tissue and cultured cells. These effects include modula
tion of gene expression and regulation of cell growth (for a
review see Refs. 1 and 2). The first step in glucocorticoid
hormone action is a reversible, noncovalent, high affinity bind
ing to its intracellular receptor. Subsequent to this, the receptor
undergoes "activation," in which it acquires the capacity to
interact with chromatin (1).
There is evidence for cross-talks between steroid hormones
and growth factors, presumably via action of their respective
receptors. Progestins have been reported to stimulate 125I-EGF3
(3) and 125I-insulin (4) binding in cultured human breast cancer
(T47D) cells. Incubation of adherent cells with progestins for
10 h resulted in a 2-fold increase in EGF binding with no
change in affinity for this binding (3). Glucocorticoids have also
been reported to enhance EGF binding in Gi-S phase synchro
nized HeLa S3 cells (5) and in quiescent human diploid foreskin
fibroblasts (6). Dexamethasone-treated human fibroblasts (HF
cells) exhibited a 50 to 100% increased ability to bind physio
logical concentrations of I25I-EGF, with maximal enhancement
after 24 h of dexamethasone treatment (6). This increase was
specific for glucocorticoids and required protein synthesis. Dex
amethasone treatment of HF cells also enhanced the mitogenic
response of these cells to EGF by 50% (6). Increased insulin
binding was observed when Swiss mouse 3T3-C2 cells were
treated with glucocorticoids (7). Maximal stimulation was ob
tained 12 h after glucocorticoid administration (3-5-fold).
Based on heavy isotope density shift experiments, it was sug
gested that this process involved decreased receptor degradation
rather than fresh insulin receptor synthesis (7). Glucocorticoids
have also been reported to either potentiate (8) or antagonize
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(9) insulin-stimulated macromolecular synthesis in different
human breast carcinoma cell lines and to inhibit growth of
breast (9,10), prostate (11), and smooth muscle (12) tumor cell
lines. Attenuation of that growth inhibition has been observed
upon growth factor addition (11-13).
Our interest in steroid receptors is derived from tests of these
substrates for the kinase action of EGF receptor in cultured
cells. Previous studies from our laboratory have shown that the
purified chick oviduct progesterone receptor is a high affinity
substrate for tyrosine phosphorylation by purified EGF (14, 15)
and insulin (15) receptor kinases. More recently, we demon
strated that EGF treatment of 32PÂ¡steady state-labeled human
breast epithelial HBL100 cells resulted in enhanced phospho
rylation of subsequently immunoprecipitated glucocorticoid re
ceptors (16). Increased phosphorylation in response to EGF
was detected on both serine and tyrosine residues. To test for
possible biological relevance of EGF-stimulated glucocorticoid
receptor phosphorylation, we examined the effects of EGF on
glucocorticoid binding and action in HBL100 cells, a nontu-
morigenic epithelial cell line derived from human milk (17).
HBL100 cells are rich in glucocorticoid receptors but exhibit
essentially no binding capacity for other steroids (18). In this
report we describe studies showing that EGF decreases gluco
corticoid binding and antagonizes its action in these cells.
MATERIALS AND METHODS
Materials. [l,2,4,6,7-3H]Dexamethasone (70 Ci/mmol) was obtained
from Amersham Corporation (Arlington Heights, IL). Unlabeled dex
amethasone, TPA, leupeptin, dithiothreitol, EDTA, ethylene glycol
bis(/3-aminoethyl ether)-N,JV,Ar',Ar'-tetraacetic acid, and phenylmeth-
ylsulfonyl fluoride were purchased from Sigma Chemical Company (St.
Louis, MO). Unless otherwise stated, all other chemicals were of
reagent grade.
Cells and Cell Culture. HBL100 cells were obtained from W. L.
McGuire (University of Texas Health Science Center, San Antonio,
TX). The cells were maintained routinely in 55-cm2 polystyrene Petri
plates in McCoy's 5A (modified) culture medium (GIBCO, Chagrin
Falls, OH) supplemented with L-glutamine (2 HIM), 10% fetal bovine
serum (GIBCO), and 10 jig/ml gentamicin at 37Â°Cin a humidified
atmosphere of 5% CO2 and 95% air. The cells were grown to near
o mil ueno and passed once a week with a change in the culture medium
on the third day after passage.
For adherent cell binding studies, unless otherwise stated, cells were
plated in 24-well polystyrene dishes (Corning Glass Works, Corning,
NY). The medium was removed from the wells 24 h later and replaced
with fresh medium containing 5% fetal bovine serum that had been
stripped of steroids by treatment with dextran-coated charcoal (18).
The cells were grown 4 days longer to about 0.7 x 10s cells/cm2 (60%
confluency).
In binding experiments involving supernatant and particulate frac
tions of cell homogenates, HBL100 cells were grown in glass roller
bottles. The roller bottles were gassed with CO2 and the cells were
cultured to approximately 80% confluency with a change in medium
on the third day of culture.
Preparation of Cell Suspensions. HBL100 cell suspensions were
obtained from cells grown in roller bottles. The cells were washed twice
with 50 ml/roller bottle of Tris-buffered saline (150 mivi NaCI and 10
mM Tris-HCl, pH 7.4). The cells were then incubated in 15 ml/roller
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bottle with Tris-EDTA [25 HIM Tris-HCl, 1 HIM NaCl, and 1 HIM
Na2HPO4 (pH 7.4 at 37Â°Q]at 37'C for 15 min to detach the cells.
During this incubation period the roller bottles were rolled continuously
at 4 rpm.
Preparation of High Speed Cytosol and Particulate Fractions following
Homogenization. Suspended cells were collected by a 4000 x gmin
centrifugation and washed twice with 5 cell pellet volumes of homoge-
nization buffer [10 mM Tris-HCl, 1 mM disodium EOT A, 5 mM
ethylene glycol bis(/3-aminoethyl ether)-A/,A^,Ar',Af'-tetraacetic acid, 2
mM phenylmethylsulfonyl fluoride, 2 mM dithiothreitol, 40 Mg/ml
leupeptin, 10 mM sodium molybdate, and 10% (v/v) glycerol (pH 7.4)].
Cells were then homogenized in 2 pellet volumes of homogenization
buffer using 50 strokes of a Dounce homogenizer in an ice bath. The
cell homogenate was centrifuged at 40,000 x gmtâ€žand the supernatant
fraction was collected. The paniculate fraction was washed with 1
volume of the homogenization buffer and centrifuged at 40,000 x gm(â€ž.
The supernatant fractions were combined and centrifuged at 6 x IO6x
gmm to obtain the high speed cytosol. The 40,000 x gmm pellet was
suspended in 3 volumes of homogenization buffer to determine dexa-
methasone binding to the particulate-associated receptors.
Extraction of Particulate Fraction-associated Glucocorticoid Receptors
at High Ionic Strength. Washed pellets were suspended in 2 volumes of
homogenization buffer containing 0.5 M KC1. The suspension was
incubated with gentle shaking on a rotating platform at 4 ( for 60 min
and then centrifuged at 40,000 x #â€žâ€žâ€ž.The supernatant fraction con
taining solubilized particulate-associated receptors was used for dexa-
methasone-binding experiments.
Dexamethasone Binding to Receptors Present in the Cytosol and Salt-
extracted Particulate Fractions. Aliquots of 50 //I from the high speed
cytosol or the particulate extract were incubated at 4Â°Cfor 16 h with
50 |il of homogenization buffer containing 0.2 to 100 nM [3H]dexa-
methasone. Three independent determinations were performed at each
dexamethasone concentration and nonspecific binding was that occur
ring in the presence of 10 ^M unlabeled dexamethasone. At the end of
the incubations, bound radioactivity was determined by the dextran-
coated charcoal assay (19). One part of dextran-coated charcoal sus
pension was added per sample and, after mixing by vortex action, the
samples were incubated at 0Â°Cfor 5 min and centrifuged at 47,000 x
Â£mm,and 50-jil aliquots of the supernatant fraction were used for
determination of radioactivity in 7 ml of aqueous counting scintillation
fluid (Amersham).
Dexamethasone Binding to Receptors Present in the Particulate Frac
tion. Dexamethasone binding to the particulate fraction was assayed
following suspension of the 40,000 x gmmpellet in 2 volumes of the
homogenization buffer. Aliquots (50 n\) of the pellet suspension were
incubated with varying concentrations of [3H]dexamethasone as de
scribed for the cytosol fraction. Bindings were terminated by centrifug-
ing the samples at 47,000 x gm,â€ž;the supernatant was aspirated off and
the pellets were washed twice by suspending the pellet in 500 n\ of
homogenization buffer followed by a 47,000 x gmiâ€žspin. The washed
pellets were extracted with 50 //' of homogenization buffer containing
0.5 M KG for 60 min at 4Â°Cwith gentle shaking on a rotating platform.
Suspensions were then centrifuged at 47,000 x gmiâ€žand 250-jil aliquots
of the supernatant fraction were quantified for radioactivity in 7 ml of
aqueous counting scintillation fluid.
Dexamethasone Binding to Adherent Cells. Unless stated otherwise,
dexamethasone binding to adherent cells was performed routinely on
cells grown in 24-well dishes. Prior to ligand binding, cells were washed
twice with 2 ml of binding medium [10 mM 4-(2-hydroxyethyl)-l-
piperazineethanesulfonic acid-buffered McCoy's Medium 5A (pH 7.4
at 37Â°C)]per well per wash and incubated in 0.5 ml of the binding
medium containing 0.2 to 75 nM [3H]dexamethasone either with or
without 3 nM EGF at 37Â°Cfor 60 min. Stock solutions of dexametha
sone were made up in 95% ethanol and the final concentration of
ethanol in the binding medium was 0.5%. Replicate assays contained
10 MMunlabeled dexamethasone for determination of nonspecific bind
ing. At the end of incubation, the 24-well dishes were placed on ice and
within 5 min the cells were washed three times with binding medium
chilled to 4"C using 2 ml per wash per well to remove free ligand. Cells
were then incubated with 200 ^i of i M NaOH for 30 min at 60Â°Cand
0.24 F
0.12 -
100 200
Dexamethasone Bound
(pM)
Fig. 1. Lack of effect of EGF on the affinity for specific dexamethasone
binding. Replicate sets of adherent HBL100 cells, grown under identical condi
tions, were incubated at 37*C for 60 min in 0.5 ml of binding medium containing
0.2 to 25 nM [3H)dexamethasone and 3 n\t EGF (â€¢)or no EGF (O). Specific
binding was determined as described in "Materials and Methods." The resulting
data were subjected to a Scatchard analysis using the LIGAND program (20). In
this experiment cells that were not treated with EGF had 9.6 Â±0.5 x iff
dexamethasone-binding sites per cell as opposed to 6.4 Â±0.1 x 10s sites per cell
for EGF-treated cells.
100 /il of the NaOH-solubilized material were neutralized with HCI
and quantified for whole cell-associated radioactivity in 7 ml of aqueous
counting scintillation fluid. For binding studies to cells grown in 6-well
dishes, the volume of binding medium used was 1 ml/well. After
completion of binding the cells were chilled and washed with 5 ml/well
of binding medium and solubilized in 1 ml of l N NaOH.
Determination of Cell Count. Cells were rinsed with 0.5 ml Tris/
EDTA and incubated in 1-5 ml of 0.25% trypsin in Hanks' salt solution
at 37Â°Cfor 20 min. Cell counts were determined using a hemocytom-
eter.
Protein Determination. Protein content in samples was determined
using a Bio-Rad protein assay kit (Bio-Rad Laboratories, Richmond,
CA) and Cohn fraction V bovine serum albumin (Sigma) as the stan
dard.
RESULTS
Dexamethasone Binding in HBL100 Cells. Adherent HBL100
cells were incubated at 37Â°Cwith 0.25 to 75 nM [3H]dexameth-
asone to achieve equilibrium binding ("Materials and Meth
ods"). Scatchard analysis of the data using the LIGAND pro
gram of Munson and Rodbard (20) revealed a single class of
high affinity binding sites (KÂ¿2 HM) with about 1 x 10s sites/
cell (not shown, but see Fig. 1).
In the course of our studies on progesterone receptor distri
bution in cultured breast carcinoma (T47D) cells we found that
progestin binding to adherent T47D cells revealed two classes
of binding affinity (21).4 These two classes of binding sites were
resolved by cell homogenization and subcellular fractionation
to yield a soluble high affinity component and a particulate-
associated low affinity component. While [3H]dexamethasone
binding to HBL100 cells revealed only a single class of high
affinity binding sites, a minor population of low affinity ligand
binding sites might have escaped detection. We therefore ex
amined dexamethasone binding in the resolved cytosolic, par
ticulate, and salt-extracted particulate fractions from HBL100
cells ("Materials and Methods"). Both the cytosolic and partic
ulate fractions displayed a single class of dexamethasone-bind
ing sites with identical affinities (Table 1). The major portion
of ligand binding activity was associated with the cytosolic
fraction; about 20% was retained in the pellet fraction. While
there was no evidence for a second, lower affinity component,
high ionic strength extraction of the particulate fraction in
creased ligand binding activity by 2-fold with no change in
affinity (Table 1).
In a separate experiment, no enhanced ligand binding activity
4J. C. Sarup, K. V. S. Rao, R. E. Williams, and C. F. Fox, submitted for
publication.
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Table 1 Scatchard analysis of specific dexamathasone binding lo the cytosolic,
paniculate, and salt-extracted paniculate fractions from HBLÃŒOOcell
homogenales
1liti ion cells grown in the glass roller bottles to about 80% confluency were
suspended, homogenized, and subjected to subcellular fractionation ("Materials
and Methods"). A portion ot the paniculate fraction was extracted in 2 volumes
of homogenization buffer containing O.S M KCI at 4'C for 60 min. Aliquots of
all the three fractions were incubated at 4'C for 16 h with 0.2 to 100 n\i | 'I l|-
dexamethasone. Nonspecific binding was that occurring in the presence of 10 /<\i
unlabeled dexamethasone. The resulting data were subjected to Scatchard analysis
using the LIGAND program of Munson and Rodbard (20). Values represent the
mean Â±SE of triplicate determinations.
SampleCytosol
Paniculate fraction
Salt extract of paniculate
fractionDexamethasone
bound (fmol/2
x IO1cells)2560
Â±333
656 Â±92
1320 Â±264Kt
(MMI1.0
Â±0.2
1.1 Â±0.2
1.6 Â±0.3
100
75
| 50
8
55 25
1 0.0 1.0 2.0 3.0 4.0 5.0
EGF CONCENTRATION (nM)
Fig. 2. Effect of EGF concentrations on specific dexamethasone binding. Cellsin 24-well dishes were washed and incubated for 60 min at 37'C in 0.5 ml of
binding medium containing 10 nM [3H)dexamethasone and EGF at the concen
trations shown. Nonspecific binding was determined as that occurring in the
presence of l Â¡IMunlabeled dexamethasone. Values represent the average Â±SD
(bars) of three separate experiments.
was observed when the cytosolic fraction was treated at high
ionic strength (not shown). High ionic strength is reported to
inactivate ligand binding activity of the rat liver glucocorticoid
receptor, but this inactivation can be overcome by including
molybdate in the extraction buffer (22), as was the case in our
experiment. Thus a significant population of dexamethasone-
binding sites in the paniculate fraction of HBL100 cells is not
accessible to ligand. The increase in binding capacity noted for
the salt extract of particulate fraction could be due either to
hitherto inaccessible receptors becoming accessible on solubil-
ization or by salt-induced activation of a cryptic population of
paniculate-associated receptors. This behavior does not appear
to be a general characteristic of glucocorticoid receptors; ex
traction of receptors from the particulate fraction of cultured
rat hepatoma cells at high ionic strength did not enhance
glucocorticoid binding (23).
Effect of EGF on Dexamethasone Binding. Adherent HBL100
cells grown to about 60% confluency were incubated with 0.01
to 20 nM I25I-EGF at 4Â°Cfor 4 h to characterize EGF binding.
Scatchard analysis of the resulting data revealed 41,000 Â±4,000
(SE) EGF-binding sites per cell. Over 95% were low affinity
sites (KA8 HM), and the remainder were high affinity sites (Ka
0.1 nM) (not shown).
Incubation of adherent cells with 10 nM [3H]dexamethasone
and 0 to 5 nM EGF caused a dose-dependent decrease in
dexamethasone binding (Fig. 2). Maximal inhibition was
achieved at 3 nM EGF with a 50% effective dose of about 0.2
nM EGF. This suggests that the high affinity component of
EGF receptors (KA0.1 nM) may facilitate the process resulting
in inhibition.
To test this, experiments were conducted in which the tumor
promoter TPA was also added to the incubation medium along
with EGF. TPA is known to inhibit formation of the high
affinity EGF binding component (24, 25), apparently by stim
ulating protein kinase C-mediated phosphorylation of EGF
receptor on Thr 654 (26). TPA inhibited dexamethasone bind
ing slightly (~15%), but simultaneous incubation with EGF
and TPA produced no additional inhibition (Table 2). On the
other hand, EGF induced a 36% decrease in dexamethasone
binding in this experiment in the absence of TPA.
Wakshull and Wharton (27) have reported that concanavalin
A prevents endocytosis of the EGF-EGF receptor complex by
mouse fibroblasts (27). The effect of concanavalin A on EGF-
induced inhibition of dexamethasone binding was studied under
conditions used in that study. HBL100 cells were first incubated
with 3 nM EGF at 4Â°Cfor 4 h and then with 200 ^g/ml
concanavalin A for 20 min at 4Â°C.The cells were then warmed
to 37Â°Cand incubated with 10 nM [3H]dexamethasone for 60
min. EGF had no effect on dexamethasone binding in concan
avalin A-treated cells but inhibited dexamethasone binding by
36% in cells not treated with concanavalin A (Table 3). Con
canavalin A alone had no significant effect on dexamethasone
binding. In agreement with the findings of Wakshull and Whar
ton (27), I25I-EGF uptake and degradation by HBL100 cells
were inhibited by greater than 50% under the conditions of
Table 3 (not shown).
Failure of EGF to Alter the Binding Affinity of Occupied
Receptors. To determine if EGF inhibits dexamethasone bind
ing by altering glucocorticoid receptor affinity as opposed to
inactivating ligand binding activity, adherent cells were incubated at 37Â°Cto achieve equilibrium binding with 0.3 to 25 nM
pHJdexamethasone in either the presence or the absence of 3
nM EGF. Scatchard analysis revealed 33% lowered dexameth
asone binding in response to EGF but no significant change in
dexamethasone binding affinity (Fig. 1). In four separate ex
periments, the Ka for dexamethasone binding was 2.3 Â±1.4 for
untreated cells and 2.1 Â±1.2 for EGF treated cells, and the
average decrease in receptor number due to EGF was 36 Â±2%.
Inhibitory Effect of EGF on Dexamethasone Binding is De
tected only in the Cytosolic Fraction of Cell Homogenates. To
Table 2 Influence of TPA on the EGF-induced decrease in dexamethasone
binding
HBL100 cells in 6-well dishes were incubated for 60 min at 37'C in 1 ml/well
of medium containing 10 nM [3H]dexamethasone and where indicated either EGF
(3 nM), TPA (100 nM), or EGF plus TPA. Nonspecific binding was determined
as that occurring in the presence of I MMnonradioactive dexamethasone. Values
represent the mean Â±SE of four determinations.
Additions
Dexamethasone bound(10-3x sites/cell)
None
EGF
TPA
EGF + TPA
99 Â±5
63 Â±5
84 Â±7
84Â± 11
Table 3 Influence of concanavalin A on the EGF-mediated decrease in specific
dexamethasone binding
H BL100 cells grown in 6-well dishes were washed, cooled to 4'C, and incubated
in 1 ml of chilled (4'C) binding medium where indicated with 3 nM EGF at 4*C
for 4 h. Concanavalin A was then added in 20 Â».1of medium to the relevant wells
where indicated at a final concentration of 200 numi: 20 ni of medium were
added to the remaining wells. All cells were incubated further for 20 min and the
temperature was then raised to 37'C. [3H)Dexamethasone was added at a final
concentration of 10 nM was added to all wells and the cells were incubated at37'C for 60 min. Values represent the mean Â±SE of five determinations.
Additions
Dexamethasone bound(10-' x sites/cell)
None
EGF
Concanavalin A
EGF - concanavalin A
96 Â±9
62 Â±10
92 Â±10
108 Â±8
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determine if EGF decreased dexamethasone binding in all
subcellular fractions, dexamethasone binding was studied in the
cytosolic, paniculate, and salt extract of the paniculate frac
tions of EGF-treated and untreated cells (Table 4). Significantly
decreased dexamethasone binding was observed only in the
cytosolic fraction in response to EGF.
Rapid Initiation and Persistence of Decreased Dexamethasone
Binding by EGF. The inhibitory effect of EGF on [3H]dexa-
methasone binding was studied as a function of time at 37Â°C.
Cells were incubated throughout the course of the experiment
with 10 nM pHjdexamethasone in the presence or absence of 3
nM EGF. The ratio of dexamethasone binding in untreated
versus EGF treated cells is presented in Fig. 3. Inhibition of
dexamethasone binding was evident as early as 2 min of EGF
Table 4 EGF decreases specific dexamethasone binding in the cytosolic fraction
of cell homogenates
HBL100 cells grown in glass roller bottles were incubated in IS ml/bottle ofbinding medium in the presence or absence of 3 nM EGF at 37"C for 60 min.
The cells were suspended and homogenized and the cytosolic, paniculate, and
salt extract of particulale fractions were obtained as described in "Materials and
Methods", except that the 4 x IO4gmiasupernatant was used as cytosol without
the additional 6 x in1'vâ€ž.â€ž,centrifugation. Dexamethasone binding in all fractions
was determined with 10 nM |3H]dexamethasone in the presence or absence of 1
>iMnonradioactive ligand ("Materials and Methods"). Values for the two inde
pendent experiments shown represent mean â€¢SE of triplicate determinations.
Addition of 0.5 M KCI to the cytosolic fraction from EGF-treated and untreated
cells and incubating at 4*C for 60 min (i.e., under conditions of paniculate pellet
salt extraction) had no effect on the EGF-induced decrease in dexamethasone
binding, indicating that the effect of EGF is stable to salt treatment.
Dexamethasone bound
(fmol/mg protein)
SampleCytosolPaniculate
fractionSalt
extract of panicu
late fractionEGF
Experiment1580
Â±81+
348 Â±49114
Â±46
+ 93Â±9500
Â±75
+ 458 Â±69Experiment
2665
Â±18454
Â±26154
Â±54
ISOÂ±37639
Â±58
613 Â±84
Fig. 3. Effect of EGF on specific dexamelhasone binding as a function of
time. A, effect over 60 min of EGF treatment. Cells in 24-well dishes were
incubated at 37'C for the times shown in 0.5 ml medium containing 10 nM | 'I l|
dexamelhasone either with or without 3 nM EGF. To determine nonspecific
binding l Â¡IMnonradioactive dexamethasone binding was also added to some
wells. Cells were processed at the times indicated to determine specifically bounddexamethasone ("Materials and Methods"). B, effect of long term incubation
with EGF. I III! inn cells were plated in 24-well dishes at a density of 0.3 x 10*
cells/cm2. At 24 h (day 0) the medium was replaced with fresh medium containing
|3H]dexamethasone either with or without EGF as described for I The cells were
incubated at 37'C for the times shown with a change in medium at day 2 (arrow).
At the times indicated cells were processed to determine specifically bounddexamethasone ("Materials and Methods"). Cell counts were determined with a
hemocytometer and dexamethasone bound was normalized for cell number.
Values represent mean values for dexamethasone bound by EGF-treated cells
expressed as a percentage of that bound by untreated cells Â±SE (bars) of
quadruplicate determinations. The down-regulation of glucocorticoid receptors
in response to glucoconicoids that has been reported for several different cell
lines (28-30) was also characteristic of FIHI i(in cells in this experiment. In the
experiment in B. dexamethasone binding in the presence or absence of EGF was
decreased by similar extents as a function of time.
treatment and was maximal within 5 min (Fig. 3A). This
decrease in dexamethasone binding persisted over 4 days (Fig.
3fi).
Insensitivity of Occupied Receptors to Short Term EGF Ac
tion. When cells were first incubated with 10 nM [3H]dexameth-
asone at 37Â°Cfor 30 min and with 3 nM EGF and [3HJ-
dexamethasone for an additional 60 min, no EGF-induced
decrease in dexamethasone binding was observed (Table 5).
EGF inhibited dexamethasone binding by approximately 40%
in the control experiment where both ligands were added to
gether (Table 5). In independent experiments we determined
that the dissociation rate of [3H]dexamethasone at 37Â°Cwas
not significantly different in EGF-treated cells which had been
incubated for 30 min at 37Â°Cwith 10 nM dexamethasone prior
to EGF addition (t>/,= 26 Â±1.5 min) or with no dexamethasone
added (f.* = 24 Â±1 min). Neither were these rates significantly
different to dexamethasone dissociation from cells not treated
with EGF (tv, = 26 Â±2 min). Taken together with the earlier
noted observation that EGF does not alter the equilibrium
binding affinity of occupied receptors (Fig. 2), EGF appears to
act by determining the number of receptors capable of binding
dexamethasone but acts in the short term to decrease binding
only to those receptors which are not saturated with ligand
(Table 5).
Antagonism of Inhibitory Action of Dexamethasone on Growth
of HBL100 Cells by EGF. Dexamethasone inhibits thymidine
incorporation in several human breast cancer cell lines, and the
extent of this inhibition correlates well with their glucocorti-
coid-binding capacity. For example, 100 nM dexamethasone
inhibited the growth of MCF-7 cells by over 50% (10). Gluco-
corticoids have been shown to inhibit proliferation of several
cultured cell lines by arresting them either in the G0 or the d
phase of the cell cycle. Growth factor addition can overcome
this inhibition (11-13). Attenuation of glucocorticoid-induced
inhibition of cell growth has been observed in prostate-derived
R3327H-G8-AI tumor cells with EGF (11) and in a smooth
muscle tumor cell line, DDTi MF-2, with platelet-derived
growth factor (12, 13).
Dexamethasone also inhibited the growth of HBL100 cells
(Fig. 4). Maximal inhibition was achieved at 100 nM dexameth
asone with a 50% effective dose of less than 5 nM (Fig. 4), in
close agreement with the observed dissociation constant for
dexamethasone binding (2 HM). Dexamethasone-induced inhi
bition of HBL100 cell proliferation was blocked by 3 nM EGF
(Fig. 5), although EGF alone had no significant stimulatory
action on HBL100 cell growth (Fig. 5). Our results are thus
consistent with observations of others (11-13).
Table 5 Insensitivity of occupied glucocorticoid receptors to short term EGF
action
HBLIOO cells were preincubated at 37'C for 30 min in 0.5 ml of binding
medium with 10 nM [3H]dexamethasone where indicated. The medium was then
removed and dexamelhasone-treated and untreated cells were divided into two
sets. To one set O.S ml medium containing 10 nM []H]dexamethasone was added
and to the other set O.S ml medium containing 10 nM [3H]dexamethasone and 3
nM EGF was added. All cells were incubated for a further 60 min at 37'C prior
to determination of specific whole cell dexamethasone binding ("Materials and
Methods"). Nonspecific binding was determined as that occurring in the presence
of l /IM unlabeled ligand. Values are mean Â±SE of five determinations.
Dexamethasone
Experimentprei cubation12Dexamethasone
bound(IO-3 xsites/cell)ControlI12Â±
13
87 Â±1391
Â±3
76 Â±6+EGF69
Â±585
Â±1570
Â±5
81 Â±11
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3.0
2.0
1.0
0.0
100
50 g
50 100 "1000
DEXAMETHASONE CONCENTRATION (nM)
Fig. 4. Effect of dexamethasone concentrations on the growth of UHI HIM
cells. HBL100 cells were plated in 6-well dishes at approximately 10* cells/cm2
and grown for 24 h. The medium was removed and replaced with 5 ml of fresh
medium containing dexamethasone as indicated. The cells were grown for 48 h
further when cell counts were determined. The values represent mean Â±SE (bars)
of four determinations.
01234
DEXAMETHASONE TREATMENT
(DAYS)
Fig. 5. EGF overcomes the growth inhibition induced by dexamethasone.
HBL100 cells were plated in 6-well dishes at approximately IO4cells/well. At day
0 (48 h later), the medium was replaced with 5 ml/well of fresh medium alone
(D) or with 100 nM dexamethasone (A), 3 nM EGF (â€¢),or 100 nM dexamethasone
plus 3 nM EGF (A). The cells were grown with a replenishment of medium every
48 h. At the designated times, cell counts were determined in I-S ml of 0.25%
trypsin solution as described in "Materials and Methods." Each point represents
the mean of four determinations. Bars, SE. Similar results were obtained in two
additional, independent experiments. The experiment in Table 6 also demon
strates the dominance of EGF over dexamethasone-induced growth inhibition.
Table 6 TPA antagonism of the stimulatory effect of EGF on growth of
dexamethasone-inhibited HBL100 cells
Cells were plated in 24-well dishes at a density of IO4cells/cm2. At day 0 (24
h later), the medium was replaced with 1 ml/well of medium containing the
various agents as shown. The concentrations used were: Dex," 100 nM; EGF, 1
nM, and TPA, 20 nM. Cells were incubated at 37*C with a change in medium
after a further 48 h (day 2). After an additional 48 h (day 4), cell counts weredetermined ("Materials and Methods"). Values are mean Â±SE of four determi
nations.
AdditionsNoneDexEGFTPADex
+EGFDex
+TPAEGF
+TPADex
+ EGF + TPAIO"5
x cellno.7.4
Â±0.684.4
Â±0.148.6
Â±0.678.2
Â±0.248.5
Â±0.775.5
Â±0.467.9
Â±0.266.0
Â±0.44%
ofcontrol(100)591161111157410781
' Dex, dexamethasone.
TPA Blockage of Antagonistic Action of EGF on Dexameth
asone-induced Inhibition of HBL100 Cell Growth. Since the
EGF-induced decrease in dexamethasone binding was antago
nized by TPA (Table 2), we determined if TPA could also block
the EGF action on dexamethasone-induced inhibition of
HBL 100 cell growth. The growth-inhibitory effect of dexa
methasone was not influenced by TPA (Table 6), and the growth
rates of cells incubated in the presence of EGF, TPA, or EGF
plus TPA were similar. However, TPA addition effectively
blocked the antagonistic effect of EGF on dexamethasone-
induced growth inhibition (Table 6).
DISCUSSION
In responsive cells, epidermal growth factor can stimulate
protein phosphorylation on tyrosine, serine, and threonine res
idues (31-36). The protein tyrosine kinase activity is a property
of the EGF receptor protein (31). The protein threonine kinase
activity can be attributed to protein kinase C (32) which acts in
turn to phosphorylate EGF receptor at Thr 654 (26, 37),
attenuating its protein tyrosine kinase activity (25, 38, 39). The
source of increased serine phosphorylation has not been estab
lished, although there are several candidate activities (33-36).
Glucocorticoid receptors are phosphorylated on serine resi
dues in a variety of tissues and cultured cells (16, 40, 41), and
more recent evidence has indicated a significant but smaller
phosphorylation complement on tyrosine residues (16). In
creased phosphorylation at both serine and tyrosine residues
has been noted in EGF-stimulated cells (16). Phosphorylation
at serine residues has been proposed to play an obligatory role
in maintaining ligand-binding activity (42, 43). No role has
been proposed for phosphorylation at tyrosine residues.
Equilibration of cells with dexamethasone at a concentration
sufficient to saturate ligand-binding sites on glucocorticoid
receptors in HBL 100 cells inhibited alkali-stable phosphoryla
tion of the glucocorticoid receptor occurring in response to
EGF (16). Preequilibration with dexamethasone also blocked
the ability of EGF to induce a short term decrease in dexa-
methasone-specific binding activity (Table 5). These experi
ments suggest a causal relationship between EGF receptor-
mediated phosphorylation of glucocorticoid receptor and EGF-
induced decreased glucocorticoid-binding activity but are not
conclusive (16). The question of whether EGF receptor inacti
vates cell-free system glucocorticoid binding by phosphorylat-
ing glucocorticoid receptors directly on tyrosine residues is a
subject currently under investigation in our laboratory.
The properties of TPA and concanavalin A in antagonizing
the ability of EGF to decrease glucocorticoid-binding activity
(Tables 2 and 3) support a causal role for EGF-dependent
protein tyrosine kinase action in decreasing glucocorticoid bind
ing but do not exclude the possibility of EGF receptor acting
through activation of other catalytic activities. The cytosolic
con line meni of the EGF effect on glucocorticoid binding (Table
4) is consistent with the localization and thus the direct action
of EGF receptor kinase and indicates that the cellular functions
of glucocorticoid receptors remaining associated with the par
ticulate fraction upon homogenization are unlikely to be af
fected by direct EGF receptor action.
While the magnitude of the effect of EGF on dexamethasone
binding is not substantial, nevertheless this interaction could
be important in regulating at least the short term effects of
glucocorticoids. Amplified responses to small changes in stim
uli are common regulatory events in biological systems (44) and
the condition has been referred to as a "threshold" phenome
non.
The mechanism by which EGF acts to attenuate HBL 100
cell growth inhibition occurring in response to dexamethasone
is not obvious from our study. It is unlikely that EGF acts to
uncouple glucocorticoid growth-inhibitory action by decreasing
glucocorticoid binding. This would require that EGF (a) act to
decrease glucocorticoid binding nearly completely in a subpop-
ulation of cells which is unique in its growth inhibition sensitiv
ity to glucocorticoids or (/>|induce preferential phosphorylation
of a unique subpopulation of glucocorticoid receptors
which are responsible for the growth-inhibitory action. While
we consider these possibilities extremely unlikely, we are pre-
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paring to test for differences in responses to glucocorticoids or
EGF in subclones of the HBL100 cell line.
The action of EGF to attenuate glucocorticoid-induced inhi
bition of HBL100 cell growth reinforces the observations of
Smith et al. (11) and Syms et al. (12) with cultured R3327H-
G8-A1 and DDTÂ¡MF-2 cells. Glucocorticoid-induced growth
inhibition of R3327H-G8-A1 and DDT,MF-2 cell growth can
be reversed nearly completely by EGF in the former case and
by platelet-derived growth factor in the latter (11, 12). This
indicates that growth factors can act through pathways inde
pendent of and dominant over those through which glucocor
ticoids act to inhibit cell growth. This underscores the value of
determining EGF receptor levels (and responsiveness) and pos
sible autocrine or paracrine EGF or transforming growth factor-
a secretion (45) in tumors in assessing the prognosis of gluco
corticoids as tumor growth inhibitors.
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